McKesson recalls Gemcitabine Injection
- Published
- 8 Jul 2026
- Units affected
- 74 units
- Agency
- FDA
- Country
- United States
The hazard
Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01
- Brand / company
- McKesson
- Codes / lots
- Lot #: CB0046, Exp. Date 06/2027
- Distribution
- Nationwide within the United States
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 8 Jul 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.